Aurora BioPharma to Attend the Fifth Annual Marcum MicroCap Conference
CAMBRIDGE, MA - May 27, 2016 - Aurora BioPharma announced that its CEO, Robert Brooks, will attend the 5th Annual Marcum MicroCap Conference on June 1-2, 2016 at the Grand Hyatt Hotel in New York City.
About Aurora BioPharma
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy, Cancer Vaccines, and combinations with Checkpoint Inhibitors. AU105 is a "living-drug" CAR T agent that has shown safety and efficacy in pre-clinical and human clinical trials. A Phase 1 clinical trial was completed in 16 Glioblastoma patients, AU105 met its endpoints of safety, tumor killing efficacy, and showed promising signals of double the median historic overall survival. Aurora is planning a randomized multi-site Phase II trial of AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial in Recurrent Glioblastoma with intracranial injection. Osteosarcoma is the most common type of bone cancer in Children and Adolescents, even after radical amputation of a limb and chemotherapy, survival is poor. A Phase 1 trial in 19 Sarcoma patients was completed, AU-105 met its endpoints of safety, with strong signs of tumor killing efficacy. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma. The Company also has an equity interest in MedVax Technologies, Inc., its p53 DC cancer vaccine MX-225 has completed a Phase II clinical trial in Small Cell Lung Cancer; and soon to complete a Phase II trial in Breast Cancer with Indoximod, an IDO inhibitor from NewLink Genetics. The Company is planning a combination trial with MX-225 and a PD-1 antibody in lung cancer with a major pharmaceutical company.
About Marcum LLP
Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation, with offices in major business markets throughout the U.S., Grand Cayman and China. Headquartered in New York City, Marcum provides a full spectrum of traditional tax, accounting and assurance services; advisory, valuation and litigation support; and an extensive range of specialty and niche industry practices. The Firm serves both privately held and publicly traded companies, as well as high net worth individuals, private equity and hedge funds, with a focus on middle-market companies and closely held family businesses. In 2015, Marcum's SEC Services Practice group led all non-"Big Four" accounting firms in the performance of audits in connection with Initial Public Offerings ("IPOs"). Marcum is a member of the Marcum Group, an organization provid ing a comprehensive array of professional services.
For media inquiries, please contact:
Tel: (617) 674-7718 - Fax: (617) 674-7701
Source: Aurora BioPharma, Inc.